Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deregulated signaling pathways in glioblastoma multiforme: molecular mechanisms and therapeutic targets.

Literature DB >> 22236189

Deregulated signaling pathways in glioblastoma multiforme: molecular mechanisms and therapeutic targets.

Hua Mao¹, Drake G Lebrun, Jingxuan Yang, Vivian F Zhu, Min Li.

Abstract

Glioblastoma multiforme (GBM) is the most malignant and aggressive type of brain tumor with an average life expectancy of less than 15 months. This is mostly due to the highly mutated genome of GBM, which is characterized by the deregulation of many key signaling pathways involving growth, proliferation, survival, and apoptosis. It is critical to explore novel diagnostic and therapeutic strategies that target these pathways to improve the treatment of malignant glioma in the future. This review summarizes the most common and important pathways that are highly mutated or deregulated in GBM and discusses potential therapeutic strategies targeting these pathways.

Entities: CellLine Chemical Disease Gene Mutation Species

Mesh：

Substances：
Antineoplastic Agents

Year: 2012 PMID： 22236189 PMCID： PMC3799884 DOI： 10.3109/07357907.2011.630050

Source DB: PubMed Journal: Cancer Invest ISSN： 0735-7907 Impact factor: 2.176

91 in total

Review 1. Uncovering therapeutic targets for glioblastoma: a systems biology approach.

Authors: Paul H Huang; Webster K Cavenee; Frank B Furnari; Forest M White
Journal: Cell Cycle Date: 2007-08-20 Impact factor: 4.534

2. Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma.

Authors: Michael D Prados; Susan M Chang; Nicholas Butowski; Rebecca DeBoer; Rupa Parvataneni; Hannah Carliner; Paul Kabuubi; Jennifer Ayers-Ringler; Jane Rabbitt; Margaretta Page; Anne Fedoroff; Penny K Sneed; Mitchel S Berger; Michael W McDermott; Andrew T Parsa; Scott Vandenberg; C David James; Kathleen R Lamborn; David Stokoe; Daphne A Haas-Kogan
Journal: J Clin Oncol Date: 2008-12-15 Impact factor: 44.544

3. Aberrant expression of zinc transporter ZIP4 (SLC39A4) significantly contributes to human pancreatic cancer pathogenesis and progression.

Authors: Min Li; Yuqing Zhang; Zijuan Liu; Uddalak Bharadwaj; Hao Wang; Xinwen Wang; Sheng Zhang; Juan P Liuzzi; Shou-Mei Chang; Robert J Cousins; William E Fisher; F Charles Brunicardi; Craig D Logsdon; Changyi Chen; Qizhi Yao
Journal: Proc Natl Acad Sci U S A Date: 2007-11-14 Impact factor: 11.205

4. A pilot study of everolimus and gefitinib in the treatment of recurrent glioblastoma (GBM).

Authors: Teri N Kreisl; Andrew B Lassman; Paul S Mischel; Neal Rosen; Howard I Scher; Julie Teruya-Feldstein; David Shaffer; Eric Lis; Lauren E Abrey
Journal: J Neurooncol Date: 2008-11-19 Impact factor: 4.130

Review 5. Conspirators in a capital crime: co-deletion of p18INK4c and p16INK4a/p14ARF/p15INK4b in glioblastoma multiforme.

Authors: David A Solomon; Jung-Sik Kim; Walter Jean; Todd Waldman
Journal: Cancer Res Date: 2008-11-01 Impact factor: 12.701

6. An integrated genomic analysis of human glioblastoma multiforme.

Authors: D Williams Parsons; Siân Jones; Xiaosong Zhang; Jimmy Cheng-Ho Lin; Rebecca J Leary; Philipp Angenendt; Parminder Mankoo; Hannah Carter; I-Mei Siu; Gary L Gallia; Alessandro Olivi; Roger McLendon; B Ahmed Rasheed; Stephen Keir; Tatiana Nikolskaya; Yuri Nikolsky; Dana A Busam; Hanna Tekleab; Luis A Diaz; James Hartigan; Doug R Smith; Robert L Strausberg; Suely Kazue Nagahashi Marie; Sueli Mieko Oba Shinjo; Hai Yan; Gregory J Riggins; Darell D Bigner; Rachel Karchin; Nick Papadopoulos; Giovanni Parmigiani; Bert Vogelstein; Victor E Velculescu; Kenneth W Kinzler
Journal: Science Date: 2008-09-04 Impact factor: 47.728

7. Identification of a PTEN-regulated STAT3 brain tumor suppressor pathway.

Authors: Núria de la Iglesia; Genevieve Konopka; Sidharth V Puram; Jennifer A Chan; Robert M Bachoo; Mingjian J You; David E Levy; Ronald A Depinho; Azad Bonni
Journal: Genes Dev Date: 2008-02-07 Impact factor: 11.361

8. A phase I trial of intratumoral administration of reovirus in patients with histologically confirmed recurrent malignant gliomas.

Authors: Peter Forsyth; Gloria Roldán; David George; Carla Wallace; Cheryl Ann Palmer; Don Morris; Gregory Cairncross; Maureen Vallee Matthews; James Markert; Yancey Gillespie; Matt Coffey; Brad Thompson; Mark Hamilton
Journal: Mol Ther Date: 2008-02-05 Impact factor: 11.454

9. Comprehensive genomic characterization defines human glioblastoma genes and core pathways.

Authors:
Journal: Nature Date: 2008-09-04 Impact factor: 49.962

10. Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma.

Authors: Tim F Cloughesy; Koji Yoshimoto; Phioanh Nghiemphu; Kevin Brown; Julie Dang; Shaojun Zhu; Teli Hsueh; Yinan Chen; Wei Wang; David Youngkin; Linda Liau; Neil Martin; Don Becker; Marvin Bergsneider; Albert Lai; Richard Green; Tom Oglesby; Michael Koleto; Jeff Trent; Steve Horvath; Paul S Mischel; Ingo K Mellinghoff; Charles L Sawyers
Journal: PLoS Med Date: 2008-01-22 Impact factor: 11.069

100 in total

1. Engineered nanoparticles for systemic siRNA delivery to malignant brain tumours.

Authors: Johan Karlsson; Yuan Rui; Kristen L Kozielski; Amanda L Placone; Olivia Choi; Stephany Y Tzeng; Jayoung Kim; Jamal J Keyes; Max I Bogorad; Kathleen Gabrielson; Hugo Guerrero-Cazares; Alfredo Quiñones-Hinojosa; Peter C Searson; Jordan J Green
Journal: Nanoscale Date: 2019-10-15 Impact factor: 7.790

Review 2. The challenges associated with molecular targeted therapies for glioblastoma.

Authors: Toni Rose Jue; Kerrie L McDonald
Journal: J Neurooncol Date: 2016-02-22 Impact factor: 4.130

3. Combined proteomics/miRNomics of dendritic cell immunotherapy-treated glioblastoma patients as a screening for survival-associated factors.

Authors: Friedrich Erhart; Matthias Hackl; Hannes Hahne; Johanna Buchroithner; Chen Meng; Simone Klingenbrunner; René Reitermaier; Katrin Fischhuber; Susanna Skalicky; Walter Berger; Sabine Spiegl-Kreinecker; Daniela Lötsch; Gerda Ricken; Bernhard Kuster; Adelheid Wöhrer; Georg Widhalm; Johannes Hainfellner; Thomas Felzmann; Alexander M Dohnal; Christine Marosi; Carmen Visus
Journal: NPJ Vaccines Date: 2020-01-16 Impact factor: 7.344

4. A Thermodynamic-Based Interpretation of Protein Expression Heterogeneity in Different Glioblastoma Multiforme Tumors Identifies Tumor-Specific Unbalanced Processes.

Authors: Nataly Kravchenko-Balasha; Hannah Johnson; Forest M White; James R Heath; R D Levine
Journal: J Phys Chem B Date: 2016-04-12 Impact factor: 2.991

10. Novel HSP90 inhibitor NVP-HSP990 targets cell-cycle regulators to ablate Olig2-positive glioma tumor-initiating cells.

Authors: Jun Fu; Dimpy Koul; Jun Yao; Shuzhen Wang; Ying Yuan; Howard Colman; Erik P Sulman; Frederick F Lang; W K Alfred Yung
Journal: Cancer Res Date: 2013-03-14 Impact factor: 12.701